Literature DB >> 17041419

Fasciitis after allogeneic peripheral blood stem cell transplantation in a patient with chronic myelogenous leukemia.

Kee Won Kim1, Chong Hyeon Yoon, Chul Seung Kay, Hee Jung Kim, Eun Hee Lee, Suk Young Park.   

Abstract

Fasciitis, one of the presentations of chronic skin graft-versus-host disease (GVHD), is characterized by symmetrical inflammatory swelling of extremities with or without eosinophilia, but it is rarely reported. This article describes a patient with the clinical and histologic features of fasciitis, as the only form of chronic GVHD that developed 20 months after HLA-matched allogeneic peripheral hematopoietic stem cell transplantation (HSCT) for chronic myelogenous leukemia (CML). She reported tightness of the skin and pain in both wrists and elbows on motion, with edema of the limbs. A deep cutaneous biopsy showed thickening of the subcutaneous fascia with inflammatory infiltrates. The patient was treated with cyclosporine and prednisone, which resulted in much improvement of her symptoms and signs related to the fasciitis. The authors recommend that clinicians maintain a high index of suspicion for fasciitis because fasciitis is a distinct entity among the chronic GVHD that may lead to a functional disability.

Entities:  

Year:  2003        PMID: 17041419     DOI: 10.1097/01.RHU.0000037772.99917.86

Source DB:  PubMed          Journal:  J Clin Rheumatol        ISSN: 1076-1608            Impact factor:   3.517


  2 in total

Review 1.  Graft versus host disease-related eosinophilic fasciitis: cohort description and literature review.

Authors:  Cristina Hidalgo Calleja; Daniel Martín Hidalgo; Concepción Román Curto; Lourdes Vázquez López; Estefanía Pérez López; Mónica Cabrero Calvo; Ana África Martín López; María Dolores Caballero Barrigón; Lucía Lopez-Corral
Journal:  Adv Rheumatol       Date:  2022-08-23

2.  Nail dystrophy, edema, and eosinophilia: harbingers of severe chronic GVHD of the skin in children.

Authors:  J T Huang; C N Duncan; D Boyer; H Khosravi; L E Lehmann; A Saavedra
Journal:  Bone Marrow Transplant       Date:  2014-09-22       Impact factor: 5.483

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.